Affinia Therapeutics
Waltham, Massachusetts, United States · Biotechnology, Health Care, research · 51 employees
Affinia Therapeutics is pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics’ pipeline of first-in-class or best-in-class product candidates in cardiovascular and neurological diseases leverages its proprietary next-generation capsids, payloads, or manufacturing approaches and have shown efficacy, safety, and different
Funding history
- Funding Round — $13.3M — Oct 2025
- Series series c — $40.0M — Oct 2025
- Funding Round — $110.0M — May 2021
- Funding Round — $38.5M — Mar 2020
Recent signals
- Oct 14, 2025: Raised $13.3M
- Oct 07, 2025: Raised $40.0M in Series series c
- Jun 03, 2025: Affinia Therapeutics Partners with DCM Foundation to Raise Awareness of BAG3 Dilated Cardiomyopathy and Promote Genetic Testing.
- Feb 05, 2025: Affinia Therapeutics Appoints Hideo Makimura, M.D., Ph.D. as Chief Medical Officer
- Nov 13, 2024: Affinia Therapeutics and Forge Biologics Announce AAV cGMP Manufacturing Partnership
- Sep 11, 2024: Affinia Therapeutics Appoints Rami Daoud as Chief Business and Financial Officer
- May 06, 2021: Raised $110.0M
- Mar 27, 2020: Raised $38.5M
See plans & pricing → Track Affinia Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.